Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and suppress overactive immune cells responsible for inflammatory and autoimmune conditions by inhibiting IL-2 and IL-15 signalling

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.